COG ADVL0314: A PHASE 1 STUDY OF BEVACIZUMAB IN REFRACTORY SOLID TUMORS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这一阶段的研究测试了一种名为贝伐单抗的新药的安全性，这种抗体可以阻断新血管的发育。没有通过新形成的血管的血液供应，肿瘤就不能生长，使用贝伐单抗进行的实验室实验表明，它可能会阻止新血管的生长。当暴露于贝伐单抗时，肿瘤可能无法生长。已经在成人身上发现了安全剂量的贝伐单抗，但还没有在儿童身上进行贝伐单抗的试验。这项研究的目的是测试贝伐单抗的安全性，看看它对儿童和儿童癌症有什么(好的和坏的)影响，并找到可以给儿童服用的最高剂量的贝伐单抗，而不会造成严重的副作用。这项研究的其他目标是了解人体如何处理药物，并更好地了解肿瘤细胞与健康细胞的不同功能。由于这一I期试验的主要目的是寻找儿童可以安全服用的贝伐单抗的最大剂量，一些患者接受的剂量可能太小，对他们的肿瘤没有任何影响，也可能太高，导致不良副作用。目前还不清楚这种药物，在任何剂量下，是否会有效地治疗这项研究中接受治疗的患者的癌症。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This phase I study tests the safety of a new experimental drug called bevacizumab, which is an antibody that works to block the development of new blood vessels. Tumors cannot grow without blood supply through newly formed blood vessels, and laboratory experiments performed with bevacizumab showed that it may block the growth of new blood vessels. Tumors may not be able to grow when exposed to bevacizumab. A safe dose of bevacizumab has already been found in adults, but there have been no trials of bevacizumab in children yet. The goals of this study are to test the safety of bevacizumab, to see what effects (good and bad) it has on children and children's cancer, and to find the highest dose of bevacizumab that can be given to children without causing severe side effects. Other goals of this study are to learn how the body handles the drug, and to better understand the functions in tumor cells that differ from healthy cells. Because the main purpose of this phase I trial is to find the maximum dose of bevacizumab that can be safely given to children, the dose that some patients receive may be too little to have any effect on their tumor, or it may be too high and cause bad side effects. It is not known if this drug, at any dose, will be effective in treating the cancer of patients treated on this study.